<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109265</url>
  </required_header>
  <id_info>
    <org_study_id>OSI2288g</org_study_id>
    <nct_id>NCT00109265</nct_id>
    <nct_alias>NCT00024219</nct_alias>
  </id_info>
  <brief_title>A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy</brief_title>
  <official_title>A Phase II, Multicenter, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of OSI-774 in Patients With Advanced or Metastatic Breast Cancer and Disease Progression During or Following Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase II, multicenter trial of single-agent treatment with OSI 774 in patients with&#xD;
      histologically confirmed, incurable, locally advanced or metastatic breast cancer. Patients&#xD;
      must have measurable disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib HCl (OSI-774)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Women &gt;=18 years of age&#xD;
&#xD;
          -  Histologically documented, incurable, locally advanced or metastatic breast cancer&#xD;
&#xD;
          -  Disease progression on or after therapy with an anthracycline, a taxane, and&#xD;
             capecitabine (Cohort 1), or disease progression on or after therapy with at least one&#xD;
             chemotherapy regimen for locally advanced or metastatic disease (Cohort 2)&#xD;
&#xD;
          -  Measurable disease of &gt;=2 cm (&gt;=1 cm on spiral CT scan). Disease at previously&#xD;
             irradiated sites is considered measurable if there is clear disease progression&#xD;
             following radiation therapy.&#xD;
&#xD;
          -  HER2 negative, HER2 unknown, or HER2 positive and disease progression following&#xD;
             Herceptin(R) (trastuzumab) therapy&#xD;
&#xD;
          -  ECOG performance status of 0 to 2&#xD;
&#xD;
          -  Life expectancy of &gt;=3 months&#xD;
&#xD;
          -  Use of effective means of contraception in women of childbearing potential&#xD;
&#xD;
          -  Ability to comply with study and follow-up procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pleural effusions or blastic bone lesions as the only manifestations of the current&#xD;
             metastatic breast cancer&#xD;
&#xD;
          -  Other primary malignancies within 5 years except for adequately treated carcinoma in&#xD;
             situ of the cervix or basal or squamous cell skin cancer&#xD;
&#xD;
          -  Symptomatic or untreated brain metastases&#xD;
&#xD;
          -  Radiotherapy, immunotherapy, hormonal therapy, or chemotherapy within 21 days prior to&#xD;
             Day 0 (6 weeks for nitrosoureas or mitomycin); prior therapy with an agent designed to&#xD;
             target either the EGFR or EGFR-specific tyrosine kinase activity&#xD;
&#xD;
          -  INR &gt;4.0 for patients receiving warfarin&#xD;
&#xD;
          -  Cumulative anthracycline and anthracenedione exposure as follows: doxorubicin &gt;450&#xD;
             mg/m, liposomal doxorubicin &gt;550 mg/m, epirubicin &gt;700 mg/m, or mitoxantrone &gt;140 mg/m&#xD;
&#xD;
          -  Cardiac ejection fraction (MUGA or echocardiogram) less than the local institution&#xD;
             lower limit of normal&#xD;
&#xD;
          -  Unstable systemic disease, including active infection, uncontrolled hypertension,&#xD;
             unstable angina, congestive heart failure, or myocardial infarction within 6 months&#xD;
             prior to Day 0, or serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  Major surgery, biopsy of a parenchymal organ, or significant traumatic injury&#xD;
             occurring within 21 days prior to Day 0&#xD;
&#xD;
          -  History of other diseases, metabolic dysfunction, physical examination finding, or&#xD;
             clinical laboratory finding giving reasonable suspicion of a disease or condition that&#xD;
             contraindicates the use of an investigational drug or that might affect the&#xD;
             interpretation of the results of the study or render the patient at high risk from&#xD;
             treatment complications&#xD;
&#xD;
          -  Abnormalities of the cornea based on history (e.g., dry eye syndrome, Sjogren's&#xD;
             syndrome), congenital abnormality (e.g., Fuch's dystrophy), abnormal slit-lamp&#xD;
             examination using a vital dye (e.g., fluorescein, Bengal-Rose), and/or an abnormal&#xD;
             corneal sensitivity test (Schirmer test or similar tear production test)&#xD;
&#xD;
          -  Gastrointestinal tract disease resulting in an inability to take oral medication or a&#xD;
             requirement for IV alimentation, prior surgical procedures affecting absorption, or&#xD;
             active peptic ulcer disease&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Any of the following abnormal baseline hematologic values: *Granulocyte count&#xD;
             &lt;=1500/uL; *Platelet count &lt;100,000/uL; *Hemoglobin &lt;9 gm/dL (transfusion permitted)&#xD;
&#xD;
          -  Any of the following abnormal baseline liver function tests: *Serum bilirubin &gt;=1.5x&#xD;
             upper limit of normal (ULN); *Serum ALT and AST &gt;=2.5x ULN (&gt;5x ULN if due to liver&#xD;
             metastases); *Alkaline phosphatase &gt;=2.5x ULN (&gt;4x ULN if due to liver or bone&#xD;
             metastases)&#xD;
&#xD;
          -  Other baseline laboratory values: *Serum creatinine &gt;=1.5x ULN or creatinine clearance&#xD;
             &lt;=60 mL/min; *Uncontrolled hypercalcemia (&gt;11.5 mg/dL); *Serum albumin &lt;=3.0 g/dL&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2009 May;115(1):115-21. doi: 10.1007/s10549-008-0055-9. Epub 2008 May 22.</citation>
    <PMID>18496750</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 26, 2005</study_first_submitted>
  <study_first_submitted_qc>April 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2005</study_first_posted>
  <last_update_submitted>July 1, 2015</last_update_submitted>
  <last_update_submitted_qc>July 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Breast Cancer</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

